Cargando…

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia

Chronic myelogenous leukemia (CML) requires the BCR/ABL tyrosine kinase for disease onset and maintenance. As a result, CML can be successfully treated with tyrosine kinase inhibitors (TKIs) such as imatinib. Most patients are maintained in a disease-suppressed state on daily TKI therapy for several...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ross, Theodora S, Mgbemena, Victoria E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904890/ https://www.ncbi.nlm.nih.gov/pubmed/27308345 http://dx.doi.org/10.4161/23723548.2014.963450

Ejemplares similares

Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia
por: Hai, Abdul, et al.
Publicado: (2014)

The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia
por: Liu, Yonglan, et al.
Publicado: (2022)

Quantification of BCR-ABL mRNA in Plasma/Serum of Patients with Chronic Myelogenous Leukemia
por: Narita, Miwako, et al.
Publicado: (2012)

Philadelphia Chromosome‐positive Chronic Myelogenous Leukemia with Deleted Fusion of BCR and ABL Genes
por: Ohyashiki, Kazuma, et al.
Publicado: (1990)

Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia
por: Mukherjee, Kaushiki, et al.
Publicado: (2017)

BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia
por: Paramita, Dewi Kartikawati, et al.
Publicado: (2020)

Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia
por: Gómez, Carmela, et al.
Publicado: (2022)

Protocol for isolation and analysis of the leukemia stem cells in BCR-ABL-driven chronic myelogenous leukemia mice
por: Liu, Chang, et al.
Publicado: (2023)

BCR‐ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia
Publicado: (2019)

Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2021)

Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis
por: Jiang, Shuoyi, et al.
Publicado: (2021)

Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
por: de Almeida Filho, T.P., et al.
Publicado: (2019)

Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells
por: De Rosa, Viviana, et al.
Publicado: (2019)

Trifolium Repens Blocks Proliferation in Chronic Myelogenous Leukemia via the BCR-ABL/STAT5 Pathway
por: Sarno, Federica, et al.
Publicado: (2020)

A Case with Coexistence of Major and Minor BCR/ABL Fusion Transcript at Lymphoblastic Crisis of Chronic Myelogenous Leukemia in Patients with Major BCR/ABL Positivity during Chronic Phase
por: Park, Sang Hyuk, et al.
Publicado: (2013)

“Preleukemic or smoldering” chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report
por: Bennett, John M., et al.
Publicado: (2014)

BCR‐ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance
por: Mikhailov, Ilya
Publicado: (2018)

Association of Chronic Myelogenous (Basophilic) Leukemia and the BCR/ABL Mutation in a Yucatan Barrow (Sus scrofa domestica)
por: Takawira, Catherine, et al.
Publicado: (2020)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

“Chronic myelogenous leukemia in primary blast crisis” rather than “de novo BCR‐ABL1‐positive acute myeloid leukemia”
por: Pastoret, Cedric, et al.
Publicado: (2017)

Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia
por: Maifrede, Silvia, et al.
Publicado: (2017)

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia
por: Bandyopadhyay, Shovik, et al.
Publicado: (2017)

New Genetic Variation in BCR gene of Major B3a2 Breakpoint BCR-ABL Fusion Gene in Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia
por: Sholikah, Tri Agusti, et al.
Publicado: (2017)

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
por: Zhou, A, et al.
Publicado: (2015)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
por: Vatanmakanian, Mousa, et al.
Publicado: (2019)

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
por: Seymour, J F, et al.
Publicado: (2014)

Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice
por: Vicente-Dueñas, Carolina, et al.
Publicado: (2012)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

Functionally Deregulated AML1/RUNX1 Cooperates with BCR-ABL to Induce a Blastic Phase-Like Phenotype of Chronic Myelogenous Leukemia in Mice
por: Yamamoto, Kiyoko, et al.
Publicado: (2013)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia
por: Molica, Matteo, et al.
Publicado: (2020)

Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan
por: Tabassum, Najia, et al.
Publicado: (2014)

bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia
Publicado: (1985)

Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia
por: Cabanas, Hélène, et al.
Publicado: (2018)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

Characteristics of BCR–ABL gene variants in patients of chronic myeloid leukemia
por: Amin, Huma, et al.
Publicado: (2021)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k2qf1a558r8gadq34j843o3571